Shandong Jincheng Pharmaceutical Group Co Ltd

Shandong Jincheng Pharmaceutical Group Co Ltd has a market capitalization of CNY 5.9 billion and a price-to-earnings ratio of 133.44, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 1.61, suggesting that the market values the company at a moderate premium to its book value. The enterprise value to EBITDA ratio is 75.73, which is significantly higher than typical industry benchmarks, indicating a high valuation relative to its operating performance. The company's liquidity position is characterized as medium, with a current ratio of 1.71, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's profitability metrics are relatively weak. The return on equity is 1.21%, and the return on assets is 0.85%, both of which are below the industry median for pharmaceutical companies. The net income of CNY 44.19 million is modest relative to the company's revenue of CNY 2.74 billion, indicating a low net profit margin. The operating income of CNY 82.87 million is also relatively low, suggesting that the company's cost structure may be a drag on profitability. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases the company's exposure to domestic economic and regulatory risks. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.1, indicating that it is primarily financed through equity. The company's long-term debt of CNY 379.34 million is relatively low compared to its total equity of CNY 3.66 billion. The company's growth trajectory is uncertain. The revenue of CNY 2.74 billion is flat compared to previous periods, and there is no indication of significant revenue growth in the near term. The company's capital expenditure of CNY -100.88 million suggests that it is not investing heavily in new projects or expansion. The free cash flow of CNY 100.40 million is positive, but it is not being reinvested into the business at a significant level. The company's risk profile is moderate. The liquidity risk is characterized as medium, and the dilution risk is low. However, the company has a negative net cash position after subtracting total debt, which could be a concern if it needs to raise additional capital. The company has not disclosed any significant dilution sources in recent filings, and there is no indication of near-term pressure to issue new shares. Recent events and filings do not indicate any major changes in the company's operations or financial position. The company's latest financial report shows a stable revenue and a modest net income, but there are no significant new developments or strategic initiatives disclosed. The company's management has not provided any forward-looking guidance that would suggest a change in the current trajectory.